Discrimination of faster eGFR decline with or without urinary SMTNL2 DNA methylation in patients with diabetes
| Model | C-statistics | NRI | Event NRI | Non-event NRI | IDI |
| Model 1 | 0.701 (0.554 to 0.816) | ||||
| Model 1+SMTNL2 | 0.759 (0.620 to 0.859) | 0.542 (p=0.02) | 13.04% | 41.18% | 0.056 (p=0.03) |
| Model 2 | 0.788 (0.664 to 0.875) | ||||
| Model 2+SMTNL2 | 0.825 (0.702 to 0.904) | 0.629 (p=0.009) | 21.74% | 41.18% | 0.084 (p=0.01) |
Model 1, eGFR and urinary log Alb/Cr.
Model 2, age, sex, eGFR, log Alb/Cr, HbA1c, use of renin-angiotensin-aldosterone system inhibitors and systolic blood pressure; SMTNL2, DNA methylation levels of SMTNL2 in urine sediment.
C-statistics are represented as mean (95% CI). Category-free NRI and IDI are represented as values (two-sided P values). Components of NRI are presented as event and non-event NRI.
eGFR, estimated glomerular filtration rate; HbA1c, glycated hemoglobin A1c; IDI, integrated discrimination improvement; log Alb/Cr, log-transformed albumin-to-creatinine ratio; NRI, net reclassification improvement.